Health and Healthcare
Dendreon, When 200% Sales Growth Is Not Enough (DNDN)
Published:
Last Updated:
Thomson Reuters has estimates of -$0.63 EPS and $81.23 million in sales. The company called this report as having exceeded its guidance of low single-digit quarter-over-quarter growth.
Dendreon had approximately $559.1 million in cash, cash equivalents and short-term and long-term investments as of March 31, down from $617.7 at the end of the December 31, 2011 period.
Without formal guidance, we cannot consider this report as “finished business” until that data is out.
Dendreon shares closed up 3.2% at $11.69 against a 52-week range of $6.46 to $42.87, and shares are down 7.3% at $10.82 in the after-hours session.
JON C. OGG
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.